CN113633719A - Antioxidant composition, preparation method and application - Google Patents
Antioxidant composition, preparation method and application Download PDFInfo
- Publication number
- CN113633719A CN113633719A CN202110933168.8A CN202110933168A CN113633719A CN 113633719 A CN113633719 A CN 113633719A CN 202110933168 A CN202110933168 A CN 202110933168A CN 113633719 A CN113633719 A CN 113633719A
- Authority
- CN
- China
- Prior art keywords
- extract
- parts
- astragalus
- dendrobium officinale
- angelica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 77
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 143
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 54
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 46
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 39
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 32
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 29
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 29
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 29
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 29
- 241001061264 Astragalus Species 0.000 claims abstract description 28
- 235000006533 astragalus Nutrition 0.000 claims abstract description 28
- 210000004233 talus Anatomy 0.000 claims abstract description 28
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 24
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 24
- 241000125175 Angelica Species 0.000 claims description 44
- 150000004676 glycans Chemical class 0.000 claims description 33
- 229920001282 polysaccharide Polymers 0.000 claims description 33
- 239000005017 polysaccharide Substances 0.000 claims description 33
- 235000019206 astragalus extract Nutrition 0.000 claims description 29
- 238000001914 filtration Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 10
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 10
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 10
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 10
- 229940114124 ferulic acid Drugs 0.000 claims description 10
- 235000001785 ferulic acid Nutrition 0.000 claims description 10
- STKUCSFEBXPTAY-GSUVRYNNSA-N methyl (4s,5z,6s)-5-ethylidene-4-[2-oxo-2-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[2-(4-hydroxyphenyl)ethoxy]oxan-2-yl]methoxy]ethyl]-6-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4h-pyran-3-carboxylate Chemical compound O([C@@H]\1OC=C([C@H](C/1=C/C)CC(=O)OC[C@@H]1[C@H]([C@H](O)[C@@H](O)[C@H](OCCC=2C=CC(O)=CC=2)O1)O)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O STKUCSFEBXPTAY-GSUVRYNNSA-N 0.000 claims description 10
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 10
- 244000241838 Lycium barbarum Species 0.000 claims description 9
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 8
- 229930183118 Tanshinone Natural products 0.000 claims description 5
- 229930183842 salvianolic acid Natural products 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000009188 angelicae sinensis extract Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 3
- 235000015468 Lycium chinense Nutrition 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 241000382455 Angelica sinensis Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 239000000126 substance Substances 0.000 abstract description 22
- 241001465754 Metazoa Species 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 11
- 230000003647 oxidation Effects 0.000 abstract description 11
- 238000007254 oxidation reaction Methods 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000003859 lipid peroxidation Effects 0.000 abstract description 4
- 230000002633 protecting effect Effects 0.000 abstract description 2
- 230000002000 scavenging effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 2
- 235000021120 animal protein Nutrition 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 14
- 210000005228 liver tissue Anatomy 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 150000002978 peroxides Chemical class 0.000 description 7
- 238000000611 regression analysis Methods 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000003064 anti-oxidating effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000009636 Huang Qi Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000009724 Salvia extract Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000556 factor analysis Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000000852 hydrogen donor Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 241001523681 Dendrobium Species 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an antioxidant composition, a preparation method and application thereof, wherein the antioxidant composition comprises astragalus, angelica, dendrobium officinale, medlar, salvia miltiorrhiza and glossy privet fruit. The invention takes astragalus, angelica, dendrobium officinale, medlar, salvia miltiorrhiza and glossy privet fruit as raw materials or extracts thereof as raw materials to be compounded and combined, and combines the modern preparation process to form a compound preparation with the functions of scavenging free radicals, resisting oxidation and aging, thereby achieving the effects of resisting oxidation and aging and protecting organisms. Animal experiments prove that the animal protein has an antioxidant function, and can improve the activities of SOD and GSH-Px in an animal body, improve the content of an antioxidant substance GSH, and reduce the content of a lipid peroxidation product MDA and a lipid peroxidation product PCO in a model animal body.
Description
Technical Field
The invention relates to a composition with an anti-oxidation effect, in particular to an anti-oxidation composition which is anti-aging, protects organisms and is simple to prepare, a preparation method and application.
Background
Human life activities can not be separated from oxygen, and in the process of utilizing oxygen molecules by a human body, free radicals are needed to assist the progress of a plurality of biochemical reactions and the synthesis of bioactive analysis components; free radicals are also involved in various functions such as energy production, regulation of cells and genes, cell signal transduction, immune killing, detoxification and the like. The antioxidant substance captures excessive free radicals in cells, prevents the free radicals from escaping, and causes oxidative damage to the cells and biological macromolecules such as DNA, protein, fatty acid and the like. The free radical has physiological functions and potential of causing pathological damage, and the free radical coexist in a symbiotic way; the antioxidant substance can maintain the flat marks of oxidation and oxidation resistance and free radical generation and quenching processes through the effect of resisting free radical damage, and promote the health of organisms.
The excessive free radicals increase the risk of complex and difficult-to-cure diseases such as cardiovascular and cerebrovascular diseases, cancers, degenerative nervous system diseases, type II diabetes and the like. Therefore, the human body should take enough antioxidants, delay the rate of body deterioration, prevent body aging, and maintain youthful spirit.
The strength of the antioxidant is reflected in the difficulty of oxidation, the antioxidant process is actually a process of competing for free radicals with a protected substance, the protein component can change the space structure of the protein through physical and chemical factors or form polypeptide due to the splitting of peptide bonds, and the reactive site of amino acid with strong antioxidant performance in the component is activated, so that the antioxidant property of the component is activated. The amino acid which is easy to become a hydrogen donor has better oxidation resistance in terms of the amino acid structure, the amino acids are cysteine (Cys), methionine (Met), phenylalanine (Phe), tryptophan (Trp), tyrosine (Tyr) and histidine (His), and in terms of the three-dimensional space structure of the whey protein, the hydrogen donors hardly overcome the space limitation to reach and capture free radicals, the enzyme acts to destroy the regular structure of the whey protein, fully expose the amino acids which are easy to become the hydrogen donors, enable the amino acids to easily reach the free radicals and capture the free radicals, the enzyme treatment not only activates the antioxidant activity of the whey protein, the hydrolysate can be better absorbed by human body, the excellent nutrition characteristics of the hydrolysate can provide effective nursing and supply for different people in specific physiological stages, thereby enabling the organism to achieve organic balance on the basis of improving the immunity and providing powerful guarantee.
With the establishment of the theory of the antioxidant symbiosis, the research of the compound antioxidant is also continuously advanced. The compound antioxidant is prepared by compounding several antioxidants with complementary functions, and compared with a single antioxidant, the compound antioxidant not only can enhance the antioxidant function, but also has a more obvious promotion effect on the immune and function maintenance of an organism.
At present, health food or medicine is prepared from excellent antioxidants in international and domestic markets, the homogenization of the health food in terms of functions is serious, the effects of the health food at the present stage mainly focus on enhancing immunity, reducing blood pressure, reducing blood fat and the like, particularly, products in the aspect of enhancing immunity occupy a great proportion.
Disclosure of Invention
In order to solve the defect that the existing antioxidant has single effect, the invention aims to provide an antioxidant composition which is combined with the modern preparation process to form a compound preparation with the functions of scavenging free radicals, resisting oxidation and resisting aging.
The invention also aims to provide a preparation method of the antioxidant composition.
The third purpose of the invention is to provide the application of the antioxidant composition.
In order to achieve the purpose, the invention adopts the following technical scheme:
an antioxidant composition comprises the following raw materials in parts by weight: 4-40 parts of astragalus or astragalus extract, 1-20 parts of angelica or angelica extract, 1-10 parts of dendrobium officinale or dendrobium officinale extract, 1-20 parts of medlar or medlar extract, 1-30 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 1-20 parts of glossy privet fruit or glossy privet fruit extract.
In the technical scheme, the main components of the astragalus are polysaccharide, flavonoid and saponin. Pharmacological research shows that the astragalus extract component has the functions of enhancing telomerase activity, resisting oxidation, resisting inflammation, regulating immunity, reducing blood fat, reducing blood sugar, protecting liver, eliminating phlegm and promoting urination, and the extract is used as a health-care product or a medicine for prolonging the life of human beings at present.
The medlar has sweet taste and mild nature, enters liver and kidney channels, has the efficacies of nourishing liver and kidney, benefiting essence and improving eyesight, is commonly used for treating symptoms such as headache, dizziness, yin deficiency, weakness, liver and kidney deficiency, epiphora induced by wind, dreaminess, spermatorrhea, soreness and weakness of waist and knees and the like, can excite cerebral nerves, enhance immunity, prevent and treat cancers, reduce cholesterol, resist aging and beautify, and has beneficial effects on the healthy riding of human bodies.
The dendrobium officinale is a common medicine for gastrointestinal diseases, has the effects of improving the membrane structure, inhibiting inflammation and ulcer reaction, promoting gastric secretion, improving the activity of digestive enzyme, promoting movement and defecation, regulating intestinal flora and the like, and has unique advantages in the aspects of improving the gastrointestinal function and preventing and treating digestive system diseases.
The angelica is a clinical common medicine, is sweet, pungent and warm in nature and flavor, enters liver, heart and spleen channels, has very wide pharmacological action, has the effect on various systems such as respiration, immunity, circulation, blood, immunity, nerves and the like, has the effects of enriching blood and activating blood, regulating menstruation and relieving pain, relaxing bowel and the like, is widely applied to various clinical departments of traditional Chinese medicine, and is well-known as 'Yawang'. Pharmacological experiments show that the angelica can play an anti-aging role from multiple angles. The astragalus root and the angelica have pharmacological effects of multiple parts by matching, and are mainly reflected in promoting hematopoiesis in multiple links and having various protective effects on heart and cerebral vessels.
The salvia miltiorrhiza is a high-efficiency medicine for promoting blood circulation and removing blood stasis, has various pharmacological activities of improving microcirculation, reducing blood pressure, expanding blood vessels, reducing blood fat, preventing and treating atherosclerosis and the like, has a protective effect on the digestive system and the central nervous system, and has obvious effects on resisting tumors, resisting bacteria and diminishing inflammation.
The glossy privet fruit belongs to tonifying medicines in traditional Chinese medicines and enters liver channels, lung channels and kidney channels, so that the glossy privet fruit has the functions of tonifying liver and strengthening waist and knees. For yin deficiency with internal heat, such as dizziness, dim eyesight, tinnitus and night sweat. The second is soreness and weakness of waist and knees, pain in waist and legs, weakness of lower limbs, early graying of hair, alopecia, visual deterioration, dry eyes and asthenopia, which are all manifestations of deficiency of liver-yin and kidney-yin, and fructus ligustri lucidi has targeted effect.
Preferably, the feed comprises the following raw materials in parts by weight: 4-20 parts of astragalus or astragalus extract, 5-20 parts of angelica or angelica extract, 1-12 parts of dendrobium officinale or dendrobium officinale extract, 1-15 parts of medlar or medlar extract, 1-10 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 4-10 parts of glossy privet fruit or glossy privet fruit extract.
Preferably, the feed comprises the following raw materials in parts by weight: 10-18 parts of astragalus or astragalus extract, 10-20 parts of angelica or angelica extract, 2-8 parts of dendrobium officinale or dendrobium officinale extract, 2-5 parts of medlar or medlar extract, 1-5 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 6-10 parts of glossy privet fruit or glossy privet fruit extract.
Preferably, the feed comprises the following raw materials in parts by weight: 16 parts of astragalus extract, 18 parts of angelica extract, 3 parts of dendrobium officinale extract, 4 parts of wolfberry fruit extract, 3 parts of salvia miltiorrhiza extract and 10 parts of glossy privet fruit extract.
Preferably, the mass fraction of astragalus polysaccharides in the astragalus extract is 35.2%, the mass fraction of ferulic acid in the angelica extract is 1%, the mass fraction of dendrobium officinale polysaccharides in the dendrobium officinale extract is 38.9%, the mass fraction of lycium barbarum polysaccharides in the lycium barbarum extract is 4.7%, and the mass fraction of specnuezhenide in the ligustrum lucidum extract is 0.8%.
In another aspect, the present invention provides a method for preparing the antioxidant composition, comprising the following steps:
1) weighing the raw materials according to the formula ratio;
2) respectively preparing extracts of the raw materials; the mass fraction of astragalus polysaccharide in the astragalus extract is 35.2%, the mass fraction of ferulic acid in the angelica extract is 1%, the mass fraction of dendrobium officinale polysaccharide in the dendrobium officinale extract is 38.9%, the mass fraction of lycium barbarum polysaccharide in the lycium barbarum extract is 4.7%, and the mass fraction of specnuezhenide in the ligustrum lucidum extract is 0.8%.
3) Mixing the different raw material extracts obtained in the step 2) uniformly to obtain the antioxidant composition.
In the technical scheme, the antioxidant composition can be prepared into a preparation; preferably prepared into a solid preparation; the solid preparation is capsule, tablet, powder, effervescent or granule.
Preferably, in the step 2), preparing the astragalus extract, heating and refluxing the astragalus raw material by using a solvent, filtering and concentrating for later use to obtain astragalus polysaccharide;
preparing an angelica extract, extracting an angelica raw material by using a solvent, filtering and concentrating for later use to obtain angelica polysaccharide and ferulic acid;
preparing a dendrobium officinale extract, extracting a dendrobium officinale raw material with a solvent, filtering and concentrating for later use to obtain dendrobium officinale polysaccharide;
preparing fructus Lycii extract, extracting fructus Lycii with solvent, filtering, and concentrating to obtain fructus Lycii polysaccharide;
preparing Saviae Miltiorrhizae radix extract, extracting Saviae Miltiorrhizae radix with solvent, filtering, and concentrating to obtain salvianolic acids and tanshinone;
preparing fructus Ligustri Lucidi extract, extracting with solvent, filtering, and concentrating to obtain specnuezhenide.
Preferably, the astragalus extract is prepared by heating and refluxing astragalus raw material with 10 times of water, filtering and concentrating for later use to obtain astragalus polysaccharide;
preparing radix Angelicae sinensis extract, extracting radix Angelicae sinensis with 10 times of water, filtering, and concentrating to obtain radix Angelicae sinensis polysaccharide and ferulic acid;
preparing a dendrobium officinale extract, leaching a dendrobium officinale raw material with 100 times of water, filtering and concentrating for later use to obtain dendrobium officinale polysaccharide;
preparing fructus Lycii extract, extracting fructus Lycii with 20 times of water, filtering, and concentrating to obtain fructus Lycii polysaccharide;
preparing Saviae Miltiorrhizae radix extract, extracting Saviae Miltiorrhizae radix with 10 times of water, filtering, and concentrating to obtain salvianolic acids and tanshinone;
preparing fructus Ligustri Lucidi extract, extracting with 10 times of water, filtering, and concentrating to obtain specnuezhenide.
In a third aspect, the invention provides an application of an antioxidant composition, and the antioxidant composition is applied to food, health products, cosmetics or medicines.
Preferably, one or more of a filler, a disintegrant or a lubricant can be added into the antioxidant composition.
The antioxidant composition can be added with auxiliary material fillers, disintegrating agents, lubricating agents, effervescent disintegrating agents and the like when being prepared into preparations, wherein the fillers are selected from one or more of starch, microcrystalline cellulose, dextrin, sucrose, lactose, mannitol and inorganic salts, the disintegrating agents are selected from one or more of dry starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose and the like, the effervescent disintegrating agents are selected from sodium bicarbonate, citric acid and the like, and the lubricating agents are selected from one or more of magnesium stearate, superfine silica gel powder, talcum powder, polyethylene glycol 400, polyethylene glycol 6000, hydrogenated vegetable oil and the like.
The antioxidant composition has antioxidant effect, and can be used as a raw material of food, medicines, health products and cosmetics.
Compared with the prior art, the invention has the following advantages:
the raw materials selected by the invention are all green, safe and effective, and the extracts of the astragalus, the angelica, the dendrobium officinale, the medlar and the glossy privet fruit are all natural products, so that the health-care tea has the advantages of good safety and favorable absorption. The compatibility of the six medicines can better play the role of antioxidation, achieve the effects of antioxidation, anti-aging and body protection.
Animal experiments prove that the antioxidant composition provided by the invention has an antioxidant function, can improve the activities of SOD and GSH-Px in an animal body, improve the content of an antioxidant substance GSH, and reduce the contents of a lipid peroxidation product MDA and a lipid peroxidation product PCO in a model animal body.
Drawings
FIG. 1 is a graphical representation of the morphological examination of mouse liver tissue under various treatments of the present invention (1000X).
Fig. 2 is a three-dimensional loading graph of the antioxidant substance and peroxygen substance of the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides a preparation method of an antioxidant composition, which comprises the following steps:
1) weighing the raw materials according to the formula ratio;
2) respectively preparing extracts of the raw materials:
preparing radix astragali extract, extracting radix astragali with 10 times of water under heating and refluxing, filtering, and concentrating to obtain radix astragali polysaccharide;
preparing radix Angelicae sinensis extract, extracting radix Angelicae sinensis with 10 times of water, filtering, and concentrating to obtain radix Angelicae sinensis polysaccharide and ferulic acid;
preparing a dendrobium officinale extract, leaching a dendrobium officinale raw material with 100 times of water, filtering and concentrating for later use to obtain dendrobium officinale polysaccharide;
preparing fructus Lycii extract, extracting fructus Lycii with 20 times of water, filtering, and concentrating to obtain fructus Lycii polysaccharide;
preparing Saviae Miltiorrhizae radix extract, extracting Saviae Miltiorrhizae radix with 10 times of water, filtering, and concentrating to obtain salvianolic acids and tanshinone;
preparing fructus Ligustri Lucidi extract, extracting with 10 times of water, filtering, and concentrating to obtain specnuezhenide;
the mass fraction of astragalus polysaccharide in the astragalus extract is 35.2%, the mass fraction of ferulic acid in the angelica extract is 1%, the mass fraction of dendrobium officinale polysaccharide in the dendrobium officinale extract is 38.9%, the mass fraction of lycium barbarum polysaccharide in the lycium barbarum extract is 4.7%, and the mass fraction of specnuezhenide in the ligustrum lucidum extract is 0.8%.
3) Mixing the different raw material extracts obtained in the step 2) uniformly to obtain the antioxidant composition.
Example 1
0g of astragalus extract, 2g of angelica extract, 2g of dendrobium officinale extract, 8g of medlar extract, 18g of salvia miltiorrhiza extract and 18g of glossy privet fruit extract.
Example 2
4g of astragalus extract, 6g of angelica extract, 5g of dendrobium officinale extract, 18g of medlar extract, 6g of salvia miltiorrhiza extract and 16g of glossy privet fruit extract.
Example 3
8g of astragalus extract, 10g of angelica extract, 8g of dendrobium officinale extract, 6g of medlar extract, 27g of salvia miltiorrhiza extract and 14g of glossy privet fruit extract.
Example 4
12g of astragalus extract, 14g of angelica extract, 0g of dendrobium officinale extract, 16g of medlar extract, 15 g of salvia miltiorrhiza extract and 12g of glossy privet fruit extract.
Example 5
16g of astragalus extract, 18g of angelica extract, 3g of dendrobium officinale extract, 4g of medlar extract, 3g of salvia miltiorrhiza extract and 10g of glossy privet fruit extract.
Example 6
20g of astragalus extract, 0g of angelica extract, 6g of dendrobium officinale extract, 14g of medlar extract, 24g of salvia extract and 8g of glossy privet fruit extract.
Example 7
24g of astragalus extract, 4g of angelica extract, 9g of dendrobium officinale extract, 2g of medlar extract, 12g of salvia miltiorrhiza extract and 6g of glossy privet fruit extract.
Example 8
28g of astragalus extract, 4g of angelica extract, 1g of dendrobium officinale extract, 12g of medlar extract, 0g of salvia extract and 4g of glossy privet fruit extract.
Example 9
32g of astragalus extract, 12g of angelica extract, 4g of dendrobium officinale extract, 0g of medlar extract, 21g of salvia miltiorrhiza extract and 2g of glossy privet fruit extract.
Example 10
36g of astragalus extract, 16g of angelica extract, 7g of dendrobium officinale extract, 10g of medlar extract, 9g of salvia extract and 0g of glossy privet fruit extract.
Example 11
40g of astragalus extract, 20g of angelica extract, 10g of dendrobium officinale extract, 20g of medlar extract, 30g of salvia extract and 20g of glossy privet fruit extract.
Materials and methods
Sample preparation: the product obtained by mixing the formulas of the 11 examples
Experimental animals: an 8-week clean-grade Kunming-breed mouse, female, with a weight of 35-40 g, was provided by Shanghai Jihui laboratory animal feeding Co.
Animals were grouped into experimental six-week-old female Kunming mice, purchased, bred for one week under laboratory conditions, acclimated, and then randomly divided into 14 groups (i.e., normal control group, aging model group, positive control group, and 11 experimental groups administered according to 11 examples), 10 of which were each weighed for the first time before the experiment began and recorded.
Animal aging model manufacturing and administration method A model of animal aging (normal control group injected with normal saline at equal dose) was manufactured by subcutaneously injecting D-galactose solution at a concentration of 50mg/mL into the back of the neck of a mouse at an injection dose of 500mg/kg.d for seven consecutive weeks at a fixed time period (nine to ten am) daily. Four weeks after injection of D-galactose, mice were initially administered by gavage. VE is given to the positive group, the intragastric administration dose is 50mg/kg. d, each experimental group is 10 times of the human body dose, the intragastric administration is carried out at 0.1mL/10g.d, and the administration lasts for 6 weeks when the normal group and the model group are intragastric administered with physiological saline with the same amount.
Determination of immune organ index
After 12h of water maze test, mice were weighed, after blood was taken from the orbit, cervical dislocation was sacrificed, spleens were aseptically taken, livers were taken, and visceral index was calculated after weighing, see table 1.
Liver index is liver mass (g)/body weight (g) × 100%.
Spleen index is spleen mass (g)/body weight (g) × 100 ‰.
TABLE 1 mouse organ index
| Examples | Spleen index (‰) | Liver index (%) |
| Blank group | 2.83±0.51* | 4.07±0.27** |
| Model set | 2.35±0.43 | 3.58±0.23 |
| Positive control group | 2.87±0.89* | 3.60±0.47 |
| 1 | 3.12±0.61* | 4.19±0.40** |
| 2 | 2.81±0.62* | 4.19±0.65** |
| 3 | 3.56±0.41** | 4.51±0.32** |
| 4 | 2.49±0.60 | 4.01±0.42** |
| 5 | 3.31±0.62* | 4.16±0.24** |
| 6 | 2.74±0.60* | 4.20±0.32** |
| 7 | 2.75±0.60* | 3.89±0.16** |
| 8 | 2.51±0.62 | 3.91±0.37** |
| 9 | 3.00±0.97** | 3.78±0.22** |
| 10 | 3.03±0.94** | 3.83±0.27** |
| 11 | 3.02±1.4** | 3.57±0.57** |
Determination of MDA, GSH-Px, SOD content/activity in serum, liver and brain tissue
To assess whether the combination can reduce oxidative stress in vivo, the MDA content in serum and liver of each group, as well as GSH, GSH-Px, SOD content/activity, were determined.
Blood is taken at 25 ℃, 4000 Xg is centrifuged for 10 minutes, supernatant is collected according to the instruction of the kit, and the contents/activities of MDA, GSH-Px and SOD in liver tissues are measured.
Preparing 10% liver homogenate of mouse, centrifuging at 25 deg.C and 4000 Xg for 10min, collecting supernatant according to kit instruction, and determining MDA, GSH-Px, and SOD content/activity in liver tissue.
TABLE 2 mouse serum antioxidant index
TABLE 3 mouse liver tissue antioxidant index
TABLE 4 antioxidant index of brain tissue of mouse
As can be seen from the results in Table 1, the liver index and spleen index of the model group mice are reduced compared with those of the blank control group, and the difference is significant (P <0.05), which indicates that the injection of D-galactose can shrink the organ index, thereby causing the reduction of the immune function of the organism, which is consistent with the previous research. The mouse organ index can be improved to different degrees in each administration group, and the administration group has significant difference compared with a model group (P < 0.05).
The MDA level in the serum of the mice in the model group rises, the difference is significantly different (P <0.05) compared with that in the blank control group, the model is successfully established, the MDA in the serum of the mice in each administration group rises, the difference is significantly different (P <0.05), and the difference is not significantly different (P >0.05) compared with that in the blank group and the positive control group.
The data in tables 2,3 and 4 show that the liver MDA of the model group mice is increased and has a significant difference (P <0.05) compared with the liver MDA of the blank group mice, and the liver MDA of the positive control group is increased and has a significant difference (P <0.05) compared with the liver MDA of the blank group mice compared with the liver MDA of the administration group mice; compared with the liver SOD and GSH-Px enzyme activity of a blank group of mice, the GSH-Px enzyme activity of a model group of mice is reduced, the GSH content is reduced, the difference has significance (P is less than 0.05), and compared with the liver SOD and GSH-Px enzyme activity of the model group of mice, the administration group 1,2,3,4 and 5 and the model group of mice, the liver SOD and GSH-Px enzyme activity of the model group of mice are increased, the GSH content is increased, and the difference has significance (P is less than 0.05).
In conclusion, the antioxidant composition can improve the activity of SOD and GSH-Px and the content of GSH of a model group mouse, reduce the content of MDA and has antioxidant activity in vivo.
Histopathological observation of mice
As shown in figure 1, the HE staining result of the liver tissue of the mouse shows that the liver tissue capsule of the normal group is composed of elastic fiber-rich dense connective tissue with uniform thickness, the liver lobules are obviously divided and regularly arranged, the center of the liver lobules is a central vein, the periphery of the liver lobules is hepatic cells and hepatic blood sinuses which are approximately radially arranged, and the hepatic cells are round and full; the liver plates are regularly and tidily arranged, and liver sinuses are not obviously expanded or extruded; no obvious abnormality in the portal area between adjacent hepatic lobules; no significant inflammatory changes were seen. Moderate and equal degeneration of liver cell granules can be seen in central veins, the periphery of the junction area and the liver parenchyma of the aging model group, and the cytoplasma is loose and lightly stained into granules; a moderate amount of focal infiltration of lymphocytes was seen around the vessels. The positive control group and the mice of the administration group have no significant difference. In conclusion, the administration group can obviously improve the inflammation and the steatosis of the model mice.
Gray scale correlation analysis preferred optimal recipe
a) Determining an analysis series
The content of MDA and PCO in a subacute aging model mouse formed by D galactose injection is increased, the enzyme activities of SOD, GSH-Px and the content of GSH are reduced, and the results show that the traditional Chinese medicine composition can resist subacute aging change, and various oxidation resistance indexes tend to be normal.
b) Dimensionless formulation of variables
Since the data of each factor in the system may be different in dimension, it is inconvenient to compare or it is difficult to obtain a correct conclusion in comparison. Therefore, dimensionless processing of the data is required when performing the grey correlation analysis. The invention adopts a standard deviation method to carry out dimensionless processing on data.
x’iThe antioxidant index is shown; x is the number ofiRepresenting the oxidation resistance index after dimensionless treatment; x is the number ofminRepresents the minimum value of the antioxidant index; x is the number ofmaxRepresents the maximum value of the antioxidant index.
c) Calculating the correlation coefficient
Xi represents the correlation coefficient of the antioxidant index; k represents the number of antioxidant indexes; i represents the experimental group; y represents a reference number sequence; ρ represents a resolution coefficient.
d) Calculating the degree of association
The correlation coefficient is a correlation degree value of each index of the comparison number series and the reference data, so that the correlation coefficient of the comparison number series and the reference data needs to be comprehensively evaluated. The results are shown in Table 5.
w represents a weight; sigma (x)i) Standard deviation representing dimensionless antioxidant index; n represents the number of antioxidant indexes.
TABLE 5 degree of correlation
e) Rank of relevance
The relevance is sorted according to the size, the bigger the relevance value is, the closer the oxidation resistance indexes of the experimental group and the normal group are, and the relevance is sequentially the normal group, 5, 4, 2, 6, 8, 7, 3, the model group, 1, 10, the positive group, 9, 11. The fifth group had the antioxidant index closest to that of the normal group, and thus was taken as the last preferred result.
Principal component analysis
The principal component analysis is a multivariate statistical method which converts a plurality of indexes into a plurality of comprehensive indexes on the premise of losing little information by using the idea of reducing dimensions. In the present invention, mouse serum, liver and brain tissues obtained by animal experiments have many antioxidant indexes, and sensory description is difficult, and no difference can be found. The main component characteristic value is calculated through R language modeling, and the result is shown in the figure, indexes such as SOD, GSH-Px and the like in the serum, the liver tissue and the brain tissue of the mouse can be well distinguished from MDA and PCO, so that the serum, the liver tissue and the brain tissue of the mouse are subjected to factor analysis respectively and the comprehensive score is calculated. Indexes such as SOD, GSH-Px and the like in mouse serum, liver tissue and brain tissue are called as F1 antioxidant substances, MDA and PCO are called as peroxidation substances, and the indexes are shown in figure 2, wherein: s represents serum, L represents liver tissue, and B represents brain tissue; 1 represents MDA content, 2 represents PCO content, 3 represents SOD activity, 4 represents GSH-Px activity, and 5 represents GSH content.
Factor analysis
The results of the factor analysis, which can be used to obtain the F1 antioxidant substance component score coefficient matrix and the F2 peroxide substance component score coefficient matrix, and calculate the combined score of the two according to the factor equation, are shown in Table 9, and in the present invention, the combined score is the level of antioxidant substance and the level of peroxide substance in the animal body, and the results are shown in tables 6 and 7:
TABLE 6F1 antioxidant ingredient score coefficient matrix
TABLE 7F2 peroxide composition score coefficient matrix
| Factor(s) | |
| S1 | 0.149 |
| S2 | 0.199 |
| L1 | 0.201 |
| L2 | 0.201 |
| B1 | 0.150 |
| B2 | 0.198 |
TABLE 9 composite score
| Group of | F1 antioxidant substance score | F2 |
| 1 | 0.38 | -1.07 |
| 2 | -0.06 | -0.84 |
| 3 | -0.26 | -0.1 |
| 4 | -0.25 | -0.5 |
| 5 | -0.29 | -0.33 |
| 6 | -0.13 | -0.62 |
| 7 | 0.12 | 0.09 |
| 8 | -0.48 | 0.21 |
| 9 | 0.18 | 1.98 |
| 10 | 0.16 | 0.86 |
| 11 | 0.51 | 0.17 |
c) Regression analysis
In the invention, the formula proportions in each administration group are different, the obtained antioxidant substance F1 and peroxide substance F2 are different, and a certain correlation exists between the substances, so that regression analysis is carried out on the result by adopting regression analysis, and astragalus is used for feedingDosage (x)1) And the dose of radix Angelicae sinensis (x)2) And dosage (x) of Dendrobium officinale3) And dosage of fructus Lycii (x)4) Saviae Miltiorrhizae radix dosage (x)5) And the dosage of fructus Ligustri Lucidi (x)6) As independent variable, with F1And F2The coefficients of the regression equations for the dependent variables were obtained by performing a multivariate nonlinear regression analysis, respectively, to obtain F1 and F2, as shown in Table 10 below:
TABLE 10 coefficients of the regression equation
Wherein: x is the number ofij＝xi·xjDenotes xiAnd xjThe interaction of (a).
From the results of regression analysis, it can be seen that F1In the regression analysis results, antioxidant substance score F1Dosage (x) with radix astragali1) And the dose of radix Angelicae sinensis (x)2) And dosage (x) of Dendrobium officinale3) And dosage of fructus Lycii (x)4) Saviae Miltiorrhizae radix dosage (x)5) And the dosage of fructus Ligustri Lucidi (x)6) And their interactions are related.
In order to compare the influence of each dependent variable on the equation, the coefficients are normalized, and the normalized coefficients are x from large to small26、x66、x24、x15、x22、x12、x4、x16、x5、x3The result shows that the interaction of the angelica and the glossy privet fruit, the angelica and the medlar, and the astragalus and the salvia has larger influence on the antioxidant substances, and in an experimental domain, the content of the antioxidant substances in the animal body can be obviously improved by increasing the dosage of the astragalus, the angelica, the medlar, the salvia and the glossy privet fruit.
At F2In the regression analysis result, the normalization coefficients are x in the descending order12、x16、x26、x66、x5、x22、x4、x24、x3、x15The results show that the astragalus root, the angelica and the rhubarb are mixedThe interaction of astragalus, glossy privet fruit, angelica and astragalus has the largest influence on the peroxide, and is in negative correlation, and in an experimental domain, the peroxide in the animal body is reduced more obviously than other medicinal materials by increasing the dosage of the glossy privet fruit. Therefore, the contents of the medicinal materials have a synergistic effect on the antioxidation of mice.
Conclusion
The anti-oxidation composition provided by the invention is prepared according to the compatibility principle of monarch, minister, assistant and guide, and the Morris water maze experiment shows that the formula can obviously enhance the learning memory capacity of mice and improve the liver index and spleen index of the mice. The SOD enzyme activity and GSH-Px enzyme activity in the serum and tissues of the mouse are improved, the GSH content is improved, and the MDA content in the mouse is reduced, which shows that the compound can improve the activity of antioxidant enzyme and reduce the generation of lipid peroxide. In conclusion, the antioxidant composition provided by the invention has an antioxidant function.
While the invention has been described with respect to a preferred embodiment, it will be understood by those skilled in the art that the foregoing and other changes, omissions and deviations in the form and detail thereof may be made without departing from the scope of this invention. Those skilled in the art can make various changes, modifications and equivalent arrangements, which are equivalent to the embodiments of the present invention, without departing from the spirit and scope of the present invention, and which may be made by utilizing the techniques disclosed above; meanwhile, any changes, modifications and variations of the above-described embodiments, which are equivalent to those of the technical spirit of the present invention, are within the scope of the technical solution of the present invention.
Claims (10)
1. The antioxidant composition is characterized by comprising the following raw materials in parts by weight: 4-40 parts of astragalus or astragalus extract, 1-20 parts of angelica or angelica extract, 1-10 parts of dendrobium officinale or dendrobium officinale extract, 1-20 parts of medlar or medlar extract, 1-30 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 1-20 parts of glossy privet fruit or glossy privet fruit extract.
2. The antioxidant composition as claimed in claim 1, comprising the following raw materials in parts by weight: 4-20 parts of astragalus or astragalus extract, 5-20 parts of angelica or angelica extract, 1-12 parts of dendrobium officinale or dendrobium officinale extract, 1-15 parts of medlar or medlar extract, 1-10 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 4-10 parts of glossy privet fruit or glossy privet fruit extract.
3. The antioxidant composition as claimed in claim 1, comprising the following raw materials in parts by weight: 10-18 parts of astragalus or astragalus extract, 10-20 parts of angelica or angelica extract, 2-8 parts of dendrobium officinale or dendrobium officinale extract, 2-5 parts of medlar or medlar extract, 1-5 parts of salvia miltiorrhiza or salvia miltiorrhiza extract and 6-10 parts of glossy privet fruit or glossy privet fruit extract.
4. The antioxidant composition as claimed in claim 1, comprising the following raw materials in parts by weight: 16 parts of astragalus extract, 18 parts of angelica extract, 3 parts of dendrobium officinale extract, 4 parts of wolfberry fruit extract, 3 parts of salvia miltiorrhiza extract and 10 parts of glossy privet fruit extract.
5. The antioxidant composition as claimed in claim 1,2,3 or 4, wherein the mass fraction of Astragalus polysaccharides in the Astragalus extract is 35.2%, the mass fraction of ferulic acid in the Angelica sinensis extract is 1%, the mass fraction of Dendrobium officinale polysaccharides in the Dendrobium officinale extract is 38.9%, the mass fraction of Lycium barbarum polysaccharides in the Lycium barbarum extract is 4.7%, and the mass fraction of specnuezhenide in the Ligustrum lucidum extract is 0.8%.
6. A method of preparing the antioxidant composition of claim 1, comprising the steps of:
1) weighing the raw materials according to the formula ratio;
2) respectively preparing extracts of the raw materials; wherein the mass fraction of astragalus polysaccharide in the astragalus extract is 35.2%, the mass fraction of ferulic acid in the angelica extract is 1%, the mass fraction of dendrobium officinale polysaccharide in the dendrobium officinale extract is 38.9%, the mass fraction of lycium barbarum polysaccharide in the lycium barbarum extract is 4.7%, and the mass fraction of specnuezhenide in the ligustrum lucidum extract is 0.8%;
3) mixing the different raw material extracts obtained in the step 2) uniformly to obtain the antioxidant composition.
7. The method for preparing the antioxidant composition as claimed in claim 6, wherein in the step 2), the astragalus extract is prepared, and the astragalus raw material is heated and refluxed with a solvent for extraction, filtered and concentrated for later use to obtain astragalus polysaccharides;
preparing an angelica extract, extracting an angelica raw material by using a solvent, filtering and concentrating for later use to obtain angelica polysaccharide and ferulic acid;
preparing a dendrobium officinale extract, extracting a dendrobium officinale raw material with a solvent, filtering and concentrating for later use to obtain dendrobium officinale polysaccharide;
preparing fructus Lycii extract, extracting fructus Lycii with solvent, filtering, and concentrating to obtain fructus Lycii polysaccharide;
preparing Saviae Miltiorrhizae radix extract, extracting Saviae Miltiorrhizae radix with solvent, filtering, and concentrating to obtain salvianolic acids and tanshinone;
preparing fructus Ligustri Lucidi extract, extracting with solvent, filtering, and concentrating to obtain specnuezhenide.
8. The method for preparing the antioxidant composition as claimed in claim 7, wherein the astragalus extract is prepared by extracting astragalus raw material with 10 times of water under heating and refluxing, filtering, and concentrating to obtain astragalus polysaccharides;
preparing radix Angelicae sinensis extract, extracting radix Angelicae sinensis with 10 times of water, filtering, and concentrating to obtain radix Angelicae sinensis polysaccharide and ferulic acid;
preparing a dendrobium officinale extract, leaching a dendrobium officinale raw material with 100 times of water, filtering and concentrating for later use to obtain dendrobium officinale polysaccharide;
preparing fructus Lycii extract, extracting fructus Lycii with 20 times of water, filtering, and concentrating to obtain fructus Lycii polysaccharide;
preparing Saviae Miltiorrhizae radix extract, extracting Saviae Miltiorrhizae radix with 10 times of water, filtering, and concentrating to obtain salvianolic acids and tanshinone;
preparing fructus Ligustri Lucidi extract, extracting with 10 times of water, filtering, and concentrating to obtain specnuezhenide.
9. Use of an antioxidant composition according to any of claims 1 to 5 in the field of food, health products, cosmetics or pharmaceuticals.
10. The use of an antioxidant composition as claimed in claim 9, wherein the antioxidant composition further comprises one or more of an adjuvant filler, a disintegrant or a lubricant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110933168.8A CN113633719B (en) | 2021-08-12 | 2021-08-12 | Antioxidant composition, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110933168.8A CN113633719B (en) | 2021-08-12 | 2021-08-12 | Antioxidant composition, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113633719A true CN113633719A (en) | 2021-11-12 |
| CN113633719B CN113633719B (en) | 2022-08-12 |
Family
ID=78421791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110933168.8A Active CN113633719B (en) | 2021-08-12 | 2021-08-12 | Antioxidant composition, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113633719B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114272306A (en) * | 2021-12-28 | 2022-04-05 | 云南省药物研究所 | Composition with antioxidation function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824533A (en) * | 2012-09-29 | 2012-12-19 | 刘永平 | Antioxidant traditional Chinese medicine composition and preparation method thereof |
| CN103127395A (en) * | 2013-03-19 | 2013-06-05 | 云南云尚生物技术有限公司 | Dendrobe anti-oxidation preparation and preparation method thereof |
| CN104922470A (en) * | 2015-05-28 | 2015-09-23 | 许江 | Antioxidative fat-reducing composition and preparation method thereof |
| CN112057522A (en) * | 2020-09-18 | 2020-12-11 | 江苏康缘药业股份有限公司 | Composition and preparation method thereof |
-
2021
- 2021-08-12 CN CN202110933168.8A patent/CN113633719B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824533A (en) * | 2012-09-29 | 2012-12-19 | 刘永平 | Antioxidant traditional Chinese medicine composition and preparation method thereof |
| CN102824533B (en) * | 2012-09-29 | 2014-06-25 | 刘永平 | Antioxidant traditional Chinese medicine composition and preparation method thereof |
| CN103127395A (en) * | 2013-03-19 | 2013-06-05 | 云南云尚生物技术有限公司 | Dendrobe anti-oxidation preparation and preparation method thereof |
| CN104922470A (en) * | 2015-05-28 | 2015-09-23 | 许江 | Antioxidative fat-reducing composition and preparation method thereof |
| CN112057522A (en) * | 2020-09-18 | 2020-12-11 | 江苏康缘药业股份有限公司 | Composition and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 曾小燕: "中药多糖体外抗氧化作用研究进展", 《亚太传统医药》 * |
| 赵鹏著: "《植物活性物质关键技术研究》", 30 September 2018 * |
| 顾闻: "特女贞苷对血管内皮细胞氧化损伤的作用研究", 《中国中西医结合杂志》 * |
| 马清林: "当归多糖的提取工艺及药理作用研究进展", 《中兽医医药杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114272306A (en) * | 2021-12-28 | 2022-04-05 | 云南省药物研究所 | Composition with antioxidation function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113633719B (en) | 2022-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN113633719B (en) | Antioxidant composition, preparation method and application | |
| CN104225417A (en) | Traditional Chinese medicine composition with function of assisting improvement of memory and preparation method thereof | |
| CN101829189B (en) | Traditional Chinese medicine composition for treating allergic dermatitis | |
| CN102357208B (en) | Traditional Chinese medicine composition for treating diabetes, hyperglycemia, hypertension, and hyperlipidemia | |
| CN105994867A (en) | Chocolate with effect of improving immunity and preparation method thereof | |
| CN103859373A (en) | Formula and preparation method of life cultivation and health preservation food helpful for preserving health during menstrual period | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| CN102198217B (en) | Skin-caring anti-aging traditional Chinese medicine composition, preparation method thereof and application thereof | |
| CN106942561A (en) | A kind of beverage composition for treating dental erosion and preparation method and application | |
| CN114177261A (en) | Chinese herbal medicine formula for preventing and treating chronic diseases and resisting cancer and protecting health | |
| CN107319534A (en) | A kind of health food of antifatigue and beauty treatment and preparation method thereof | |
| CN103830558A (en) | Anti-aging composition and preparation method thereof | |
| CN111956736A (en) | Hypoglycemic composition mainly comprising sparassis crispa as well as preparation method and application thereof | |
| CN107751856A (en) | One seed oyster health food and preparation method thereof | |
| CN113456732B (en) | Composition for removing chloasma and preparation method thereof | |
| CN103859370A (en) | Health-preserving health food formula beneficial for beautifying and nourishing faces and preparation method thereof | |
| CN107198766B (en) | Traditional Chinese medicine composition for beautifying and preparation method and application thereof | |
| KR102217263B1 (en) | Detox composition for skin | |
| CN107536016A (en) | A kind of cardioprotection and the nutraceutical for promoting liver health | |
| CN108813617B (en) | Composition containing pilose antler, ginseng and medlar and preparation method thereof | |
| CN112494600A (en) | A Chinese medicinal composition for delaying cell and blood vessel aging | |
| CN105497519A (en) | Preparation method for radix ginseng rubra-colla corii asini cell-wall breaking superfine powder | |
| CN1401391B (en) | Use of casein and polypeptide in Chinese herbal medicine/Chinese patent medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |